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Three siblings with familial non-medullary
thyroid carcinoma: a case series
Muhammad Owais Rashid1*, Naeemul Haq1, Saad Farooq2, Zareen Kiran1, Sabeeh Siddique3, Shahid Pervez3
and Najmul Islam1

Abstract
Background: In 2015, thyroid carcinoma affected approximately 63,000 people in the USA, yet it remains one of
the most treatable cancers. It is mainly classified into medullary and non-medullary types. Conventionally, medullary
carcinoma was associated with heritability but increasing reports have now begun to associate non-medullary
thyroid carcinoma with a genetic predisposition as well. It is important to identify a possible familial association in
patients diagnosed with non-medullary thyroid carcinoma because these cancers behave more destructively than
would otherwise be expected. Therefore, it is important to aggressively manage such patients and screening of
close relatives might be justified. Our case series presents a diagnosis of familial, non-syndromic, non-medullary
carcinoma of the thyroid gland in three brothers diagnosed over a span of 6 years.
Case presentations: We report the history, signs and symptoms, laboratory results, imaging, and histopathology of
the thyroid gland of three Pakistani brothers of 58 years, 55 years, and 52 years from Sindh with non-medullary
thyroid carcinoma. Only Patients 1 and 3 had active complaints of swelling and pruritus, respectively, whereas
Patient 2 was asymptomatic. Patients 2 and 3 had advanced disease at presentation with lymph node metastasis.
All patients underwent a total thyroidectomy with Patients 2 and 3 requiring a neck dissection as well. No previous
exposure to radiation was present in any of the patients. Their mother had died from adrenal carcinoma but also
had a swelling in the front of her neck which was never investigated. All patients remained stable at follow-up.
Conclusions: Non-medullary thyroid carcinoma is classically considered a sporadic condition. Our case report
emphasizes a high index of suspicion, a detailed family history, and screening of first degree relatives when
evaluating patients with non-medullary thyroid carcinoma to rule out familial cases which might behave more
aggressively.
Keywords: Familial, Non-medullary carcinoma, Thyroid, Case series

Background
According to the American Cancer Society, in 2015 the
number of people with thyroid cancer in the USA was approximately 63,000 and it caused 2000 deaths [1]. Approximately 1.1 % of people will be diagnosed with it at
some point in their life, yet it remains one of the most
treatable cancers with a median 5-year survival rate of 98
% [1]. Thyroid cancer is divided into two chief types: medullary, which arises from parafollicular C cells, and nonmedullary, which arises from follicular epithelial cells.
Non-medullary thyroid carcinoma (NMTC) includes
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papillary thyroid carcinoma, follicular thyroid carcinoma,
Hürthle cell carcinoma, and anaplastic thyroid carcinoma
and these make up 95 % of thyroid malignancies of which
papillary carcinoma is the most common [2]. Although
medullary carcinoma is traditionally associated with a genetic predisposition and a susceptibility gene, RET, has been
identified, increasing evidence is now accumulating about
the heritability of NMTC as well [2]. Familial NMTC
(FNMTC) is defined as two or more first-degree relatives
affected by thyroid cancer without another familial syndrome; this familial clustering has been reported in 3.5 to
10.0 % of cases [1, 3]. Heritability is usually in the form of
syndromes such as familial adenomatous polyposis, Cowden syndrome, and Werner syndrome where the majority
of tumors are in organs other than the thyroid. Non-
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syndromic FNMTC is a rare entity which most likely follows an autosomal dominant path with incomplete penetrance and variable expression [3].

Case presentations
Patient 1

A 58-year-old Muhajir Pakistani man presented to our
surgery clinic with a swelling in his neck of 5 days’ duration, which he had noticed while shaving. On physical
examination he had a left-sided thyroid nodule, approximately 6×4 cm with no lymphadenopathy. He was advised
to have a thyroid function test, a thyroid ultrasound, and
fine-needle aspiration (FNA) of the suspicious nodule. His
laboratory investigations on follow-up showed thyroidstimulating hormone (TSH) of 1.58 (0.4 to 4.2), thyroxine
(T4) of 7.83 (5.1 to 14.1), and triiodothyronine (T3) of 1.99
(1.3 to 3.1). Ultrasonography of his thyroid gland revealed
a multinodular goiter with largest nodule measuring
1.1×0.8 cm in right lobe and 2.3×1.2 cm in left lobe.
Ultrasound-guided FNA of the left lobe of his thyroid
showed a follicular lesion. According to American Thyroid
Association (ATA) classification he was classified as an
intermediate risk patient. A left lobectomy was planned
for him but perioperative frozen section examination of
the left lobe revealed a follicular carcinoma (Fig. 1a, b);
therefore, a total thyroidectomy was performed and the
tumor was completely resected. Surprisingly, histopathology of the thyroid specimen (right lobe) showed thyroid
parenchyma infiltrated by a neoplastic lesion which had a
papillary architecture (Fig. 2a, b). The papillary carcinoma
measured 2×1.5×1 cm and was 0.2 cm away from the capsule; the follicular carcinoma measured 6×6 cm with no
capsular breech. The cancer had a non-aggressive histology and no lymph nodes were involved. Well-formed
papillary fronds were identified with prominent fibrovascular cores. In addition, psammoma bodies were also seen.
After the surgery, he received 5550 MBq (150 mCi) radioactive iodine131 (RAI131) for remnant thyroid tissue ablation. His postoperative stimulated thyroglobulin levels
were 19.10 (1.6 to 59.9) with a TSH of 39.12 (0.4 to 4.2).
At 6-month follow-up, his stimulated thyroglobulin had
increased to 56.56 ng/dl (1.6 to 59.9) with TSH of 94.66
(0.4 to 4.2). An ultrasound of his neck was normal and a
whole body scan was negative; therefore, no distant metastasis was present. Considering the above laboratory
values a second dose of 3700 MBq (100 mCi) iodine131
was given. He has been on regular follow-ups for the last
6 years without any evidence of recurrence.
Patient 2

Patient 2 is a younger brother of Patient 1; Patient 2 is a
55-year-old man from Karachi, Pakistan who underwent a
thyroid ultrasound for screening purposes although he
was asymptomatic. No abnormality was noted on physical

Fig. 1 a Low power view of thyroid neoplasm with follicular
arrangement. Invasion into capsular blood vessels can be seen in
the bottom right of the image. b High power view of thyroid
neoplasm with follicular arrangement. Nuclear features of papillary
thyroid carcinoma are not visible

examination. His ultrasound showed an enlarged right
lobe as compared to the contralateral side measuring
20.2×24.3×39.5 mm. At least three hypoechoic nodules
with predominant solid components were seen in his right
lobe with tiny calcification present within. The largest
nodule measured 20.8×17.0 mm. Ultrasound-guided FNA
revealed clusters and groups of follicular cells with architectural atypia, with a few of the cells forming papillary
structures. Some nuclear grooving and intranuclear inclusions were seen with a group of Hürthle cells against a
background of hemorrhage. He was classified as ATA
intermediate risk and underwent total thyroidectomy with
central neck dissection at another tertiary care facility. His
histopathology report revealed a classic papillary thyroid
carcinoma, 5.0 cm in diameter, with minimal extra thyroidal extension (right thyroid lobe). In addition, papillary
microcarcinoma, Hürthle cell variant (0.5 cm), and follicular adenoma (left thyroid lobe) were reported as well with
level VI lymph node micrometastasis. However, no capsular invasion was seen. He received postoperative 5550
MBq (150 mCi) RAI131 for remnant tissue ablation and
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guidelines. He underwent total thyroidectomy with bilateral selective neck dissection: level II, III, IV and VI. Histopathology confirmed papillary carcinoma, classic variant,
which was 7×5.5×3 cm with capsular invasion and lymph
node metastasis to level II, II, IV and IV bilaterally with no
distant metastasis (Fig. 3a, b). He received postoperative
6660 MBq (180 mCi) RAI131 for remnant thyroid tissue
ablation; he was started on suppressive thyroid hormone
therapy. His follow-up ultrasound at 6 months showed a
14×11 mm heterogeneous area in his right paratracheal
region with few lymph nodes and preserved hilum. The
largest lymph node was on the right side and measured
15×5 mm. His thyroglobulin level was 46 ng/dl (1.6 to
59.9) whereas a whole body RAI131 scan was negative for
residual disease. He underwent a positron emission tomography (PET) scan which showed a hypermetabolic, 8
mm right level II node: standardized uptake value (SUV)
of 5.2. He therefore underwent a second surgery for residual disease and right-sided neck dissection in 2015.
Histopathology showed metastatic lymph nodes. He has
kept regular follow-ups for 2 years.

Fig. 2 a Low power view of thyroid parenchyma showing a neoplastic
lesion with papillary architecture. Scattered calcification is shown. b High
power view of neoplastic cells exhibiting nuclear enlargement, crowding,
clearing, grooves, and pseudoinclusions

was started on suppressive thyroid hormone replacement.
He has been in follow-up for 3 years with no evidence of
residual or recurrent disease.
Patient 3

Patient 3 is the youngest brother of the family; Patient 3
is a 52-year-old Pakistani man who visited an endocrinologist in another hospital with the complaint of chronic urticaria. He had no other symptoms and had a normal
physical examination. He was advised to have thyroid antibody tests which showed anti-thyroid peroxidase (TPO)
of 695.10 (normally less than 35) and anti-thyroglobulin of
29.50 (normally less than 40). A thyroid function test
showed TSH of 1.80 (0.4 to 4.2), T4 of 8.80 (4.6 to 10.5),
and T3 of 2.01 (1.23 to 3). Considering the strong family
history of papillary thyroid carcinoma, he was advised to
have a thyroid ultrasound which showed a multinodular
goiter. Fine-needle aspiration cytology (FNAC) revealed
papillary carcinoma of the thyroid. A few clinically suspicious lymph nodes were also present bilaterally and he
was classified as a high risk patient according to ATA

Fig. 3 a Lymph node showing metastatic deposits. b Tumor with
intranuclear inclusions
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Discussion
To the best of our knowledge this is the first case series
reported of familial non-medullary carcinoma of the thyroid from Pakistan. Because the number of affected patients was more than two it is highly unlikely that the
NMTC was due to sporadic mutations. No specific gene
has been associated with heritability; therefore, no genetic testing is available to check for the specific gene.
Therefore, clinicians have to rely on a strong family history of this variant of thyroid cancer to diagnose familial
cases. In our case series, three brothers were affected;
Charkes stated that when three or more family members
are affected the probability of this due to sporadic mutations is less than 6 %; thus, we believe that FNMTC in
our patients due to sporadic mutations is highly unlikely
[4]. Although some researchers argue that familial clustering could be due to environmental exposure and bias
due to more aggressive screening in asymptomatic family members, increasing evidence is now accumulating
on the hereditability of NMTC. In our study, Patient 1
had a follicular carcinoma in the left and papillary carcinoma in the right lobe, respectively. In addition, Patient 2 had a classic papillary thyroid carcinoma along
with papillary microcarcinoma, Hürthle cell variant, and
follicular adenoma (left thyroid lobe), suggesting similar
genetic mutations in the pathogenesis of FNMTC. As
yet, the underlying genetic mutation involved in
FNMTC has not been identified, although it has been
suggested that FNMTC is a polygenic cancer syndrome
as several susceptibility genes and candidate chromosomal loci have been reported [5–7].
All three of our patients had minimal symptoms but
advanced disease at presentation. Lymph nodes metastasis was seen in Patients 2 and 3 whereas capsular invasion was present in Patient 3 only. This aggressive
picture is supported by a meta-analysis by Wang et al.
which showed that FNMTC is more aggressive at presentation with a higher degree of recurrence due to increased multifocality, extrathyroid invasion, bilateral
presentation, and lymph node involvement and is associated with less disease-free survival as compared to sporadic NMTC [8]. It is also associated with anticipation,
widespread disease at presentation and a worse outcome
when compared to the first generation [9]. The best predictors of prognosis are the number of family members
affected and metastasis at presentation, both of which
increase mortality [10]. However, one study suggested
that if treated early, FNMTC does not decrease life expectancy of patients [11].
Total thyroidectomy was performed for all patients with
additional neck dissection for Patients 2 and 3. Furthermore, all three patients were given RAI131. This signifies
the role of aggressive treatment in the face of FNMTC.
Sippel et al. recommend this approach followed by RAI
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and thyroid hormone suppression therapy to prevent recurrence and decrease mortality [3].

Conclusions
As specific gene testing is not available, identification of
cases of FNMTC relies on a good family history and detailed pedigree analysis. In cases where clinical data suggest the presence of FNMTC, ultrasound should be used
for the screening of close relatives for earlier diagnosis
and better outcomes. Since FNMTC is known to be particularly aggressive, patients should be a treated with
total thyroidectomy and neck dissection and kept under
close follow-up with regular evaluations to detect
recurrences.
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